Try our mobile app

Switch to company model in "Rising Stars" logic    *

General information

Country: UNITED STATES

Sector: Medical Instruments and Supplies

STAAR Surgical Company develops, manufactures, and markets high margin visual implants that improve a patient"s quality of vision. The Company manufactures implantable contact lenses to treat refractive disorders such as myopia. STAAR also manufactures products for cataract surgery and glaucoma surgery.
Website: staar.com


  • Good financial results growth rate 96.2% (average between last period year over year growth for revenue and EBITDA), there is acceleration compared to average historical growth rates (-0.4%)
  • Dividend yield for the last twelve months 0.0%
  • Free cash flow yield 1.0% (LTM)
  • Share price is 88.8% higher than minimum and 51.0% lower than maximum for the last 3 years
  • The company is overvalued by EV / LTM EBITDA multiple compared to target level (500.0x vs 30.0x)
  • For the last 3 months insiders bought company shares on $12.3 mln (1.350% of cap.)

Key Financials (Download financials)

Ticker: STAA
Share price, USD:  (-3.6%)28.49
year average price 22.74  


year start price 16.67 2025-06-04

min close price 16.34 2025-06-20

max close price 33.49 2026-05-26

current price 28.49 2026-06-03
Common stocks: 49 633 000

Dividend Yield:  0.0%
Last revenue growth (y/y):  +6.7%
Last growth of EBITDA (y/y):  +185.7%
Historical revenue growth:  -0.9%
Historical growth of EBITDA:  0.0%
EV / Sales: 5.5x
Margin (EBITDA LTM / Revenue): -38.5%

Target EV / EBITDA (hist percentile): 30.0x
Express share price potential:
EV / LTM EBITDA mutiple calculation
Market Cap ($m): 1 414
Net Debt ($m): -137
EV (Enterprise Value): 1 277
EBITDA LTM (млн $): -89
Price to Book: 4.0x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / EBITDA

Potential dynamics

News


2025-12-30fool.com

New $17 Million Bet on STAAR Surgical Comes as Sales Jump 7% and Margins Hit 82%

2025-12-16businesswire.com

Yunqi Capital Comments on Proxy Advisors' Updated Recommendations, Urges Shareholders to Continue to Back the Company's Standalone Trajectory

2025-10-22reuters.com

Staar Surgical's top investor calls shareholder meeting to remove directors

2025-09-29prnewswire.com

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates STAA and CYBR on Behalf of Shareholders

2025-09-27globenewswire.com

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates STAA and CYBR on Behalf of Shareholders

2025-09-24globenewswire.com

STAAR SHAREHOLDER ALERT: Kaskela Law LLC Investigates Fairness of Proposed STAAR Surgical Company (NASDAQ: STAA) Shareholder Buyout and Encourages Investors to Contact the Firm to Discuss their Legal Rights and Options

2025-09-15businesswire.com

Shareholder Alert: The Ademi Firm Continues to Investigate Whether STAAR Surgical Company Is Obtaining a Fair Price for Its Public Shareholders

2025-08-11zacks.com

Staar Surgical (STAA) International Revenue in Focus: Trends and Expectations

2025-08-07prnewswire.com

SHAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of STAAR Surgical Company (NASDAQ: STAA)

2025-08-05globenewswire.com

STAA Alert: Monsey Firm of Wohl & Fruchter Investigating Fairness of the Sale of STAAR Surgical to Alcon
More information for subscribed users:
detailed calculation of
Fundamental value created in LTM

Financial reporting

Income Statement

Property 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4
date 2025-09-26 2025-06-27 2024-12-27 2024-09-27 2024-06-28 2024-03-29 2023-12-29 2023-09-29 2023-06-30 2023-03-31 2022-12-30 2022-09-30 2021-12-31 2021-01-01
symbol STAA STAA STAA STAA STAA STAA STAA STAA STAA STAA STAA STAA STAA STAA
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 718 937 718 937 718 937 718 937 718 937 718 937 718 937 718 937 718 937 718 937 718 937 718 937 718 937 718 937
fillingDate 2025-11-05 2025-08-06 2024-10-30 2024-08-07 2024-05-07 2023-11-06 2023-08-02 2023-05-03 2022-11-02
acceptedDate 2025-11-05 16:06:04 2025-08-06 16:05:55 2025-02-21 16:00:40 2024-10-30 16:08:13 2024-08-07 16:06:04 2024-05-07 16:11:10 2024-02-27 06:04:44 2023-11-06 06:05:24 2023-08-02 16:11:49 2023-05-03 16:12:08 2023-02-22 21:32:23 2022-11-02 16:11:28 2022-02-23 16:21:49 2021-02-24 16:15:59
calendarYear 2025 2025 2024 2024 2024 2023 2023 2022 2022
period Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q1 Q4 FY Q3 FY FY
revenue 95M 44M 314M 89M 99M 77M 322M 80M 92M 74M 284M 76M 230M 163M
costOfRevenue 17M 12M 74M 20M 21M 16M 70M 17M 22M 16M 61M 16M 52M 45M
grossProfit 78M 33M 240M 68M 78M 61M 253M 64M 71M 58M 223M 60M 179M 118M
grossProfitRatio 0.822 0.74 0.773 0.792 0.789 0.792 0.766 0.783 0.795
researchAndDevelopmentExpenses 9M 10M 54M 14M 14M 13M 44M 11M 12M 10M 36M 10M 34M 32M
generalAndAdministrativeExpenses 21M 21M 90M 22M 24M 23M 72M 19M 18M 18M 55M 14M 44M 34M
sellingAndMarketingExpenses 23M 26M 108M 27M 29M 27M 108M 27M 32M 26M 89M 23M 67M 46M
sellingGeneralAndAdministrativeExpenses 44M 47M 198M 48M 52M 50M 180M 46M 50M 44M 144M 37M 111M 80M
otherExpenses 6M 5M 0 0 63 000 838 000 0 145 000 10000 63 000 0 0 0 0
operatingExpenses 59M 63M 252M 63M 67M 63M 225M 57M 62M 55M 180M 47M 145M 112M
costAndExpenses 76M 74M 327M 83M 87M 80M 294M 74M 84M 71M 241M 62M 197M 157M
interestIncome 790 000 1M 6M 0 1M 2M 7M 2M 2M 0 2M 0 238 000
interestExpense 0 0 0 0 0 0 0 0 0 2M 0 897 000 38 000 0
depreciationAndAmortization 2M 2M 7M 2M 2M 1M 5M 1M 1M 1M 5M 853 000 4M 3M
ebitda 26M -23M -6M 7M 13M -1M 33M 9M 12M 4M 48M 15M 37M 10M
ebitdaratio 0.279 -0.513 0.084 0.136 -0.013 0.112 0.129 0.053 0.191
operatingIncome 18M -30M -13M 6M 12M -2M 28M 6M 9M 3M 44M 14M 33M 7M
operatingIncomeRatio 0.195 -0.676 0.064 0.12 -0.029 0.078 0.093 0.038 0.18
totalOtherIncomeExpensesNet 300 000 4M 4M 7M -2M 70 000 6M -1M -2M 2M 2M -1M -2M 1M
incomeBeforeTax 19M -26M -9M 13M 10M -2M 34M 7M 8M 5M 46M 13M 31M 8M
incomeBeforeTaxRatio 0.198 -0.585 0.149 0.104 -0.029 0.084 0.092 0.064 0.165
incomeTaxExpense 10M -9M 11M 3M 3M 1M 12M 2M 2M 2M 6M 2M 4M 2M
netIncome 9M -17M -20M 10M 7M -3M 21M 5M 6M 3M 40M 10M 28M 6M
netIncomeRatio 0.094 -0.379 0.113 0.075 -0.043 0.06 0.066 0.037 0.135
eps 0.18 -0.34 -0.41 0.2 0.15 -0.068 0.44 0.099 0.13 0.06 0.83 0.21 0.52 0.13
epsdiluted 0.18 -0.34 0.2 0.15 -0.068 0.098 0.12 0.05 0.21
weightedAverageShsOut 50M 50M 49M 49M 49M 49M 49M 49M 48M 48M 48M 48M 47M 46M
weightedAverageShsOutDil 50M 50M 49M 50M 50M 49M 49M 49M 50M 50M 49M 50M 49M 48M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link
filingDate 2025-02-21 2024-02-27 2023-02-23 2022-02-23 2021-02-24
fiscalYear 2024 2023 2022 2021 2020
netInterestIncome 6M 7M 2M -38 000 238 000
ebit -13M 28M 44M 33M 7M
nonOperatingIncomeExcludingInterest 0 0 0 0 0
netIncomeFromContinuingOperations -20M 21M 40M 28M 6M
netIncomeFromDiscontinuedOperations 0 0 0 0 0
otherAdjustmentsToNetIncome 0 0 0 0 0
netIncomeDeductions 0 0 0 0 0
bottomLineNetIncome -20M 21M 40M 28M 6M
epsDiluted -0.41 0.43 0.8 0.5 0.12

Balance Sheet Statement

Property 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4
date 2025-11-05 2025-06-27 2024-12-27 2024-09-27 2024-06-28 2024-03-29 2023-12-29 2023-09-29 2023-06-30 2023-03-31 2022-12-30 2022-09-30 2021-12-31 2021-01-01
symbol STAA STAA STAA STAA STAA STAA STAA STAA STAA STAA STAA STAA STAA STAA
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 718 937 718 937 718 937 718 937 718 937 718 937 718 937 718 937 718 937 718 937 718 937 718 937 718 937 718 937
fillingDate 2025-11-05 2025-08-06 2024-10-30 2024-08-07 2024-05-07 2023-11-06 2023-08-02 2023-05-03 2022-11-02
acceptedDate 2025-11-05 16:02:30 2025-08-06 16:05:55 2025-02-21 16:00:40 2024-10-30 16:08:13 2024-08-07 16:06:04 2024-05-07 16:11:10 2024-02-27 06:04:44 2023-11-06 06:05:24 2023-08-02 16:11:49 2023-05-03 16:12:08 2023-02-22 21:32:23 2022-11-02 16:11:28 2022-02-23 16:21:49 2021-02-24 16:15:59
calendarYear 2025 2025 2024 2024 2024 2023 2023 2022 2022
period Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q1 Q4 FY Q3 FY FY
cashAndCashEquivalents 176M 167M 144M 164M 193M 224M 183M 127M 95M 90M 86M 129M 200M 152M
shortTermInvestments 17M 23M 86M 72M 42M 21M 38M 61M 97M 114M 125M 82M 0 0
cashAndShortTermInvestments 193M 190M 230M 236M 235M 245M 221M 188M 192M 204M 212M 211M 200M 152M
netReceivables 64M 37M 79M 108M 96M 68M 98M 112M 94M 63M 66M 58M 47M 35M
inventory 53M 53M 43M 40M 39M 39M 35M 31M 25M 28M 24M 20M 17M 18M
otherCurrentAssets 12M 13M 980 000 13M 14M 14M 7M 16M 16M 132M 811 000 8M 636 000 5M
totalCurrentAssets 321M 293M 368M 397M 384M 366M 365M 347M 328M 313M 312M 297M 271M 216M
propertyPlantEquipmentNet 104M 107M 122M 120M 113M 107M 101M 98M 88M 85M 82M 78M 68M 33M
goodwill 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M
intangibleAssets 0 0 0 0 0 0 0 0 0 165 000 173 000 171 000 218 000 270 000
goodwillAndIntangibleAssets 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M
longTermInvestments 0 0 0 0 265 000 7M 12M 14M 18M 13M 14M 13M 0 0
taxAssets 2M 12M 788 000 5M 5M 5M 5M 9M 5M 5M 9M 4M 4M 5M
otherNonCurrentAssets 27M 24M 17M 14M 9M 6M 3M 2M 954 000 956 000 957 000 808 000 822 000 608 000
totalNonCurrentAssets 135M 145M 142M 140M 129M 127M 123M 124M 113M 106M 107M 98M 74M 41M
otherAssets 0 0 0 0 0 0 0 0 0 0 0 0 0 0
totalAssets 456M 438M 510M 538M 513M 493M 489M 472M 441M 419M 419M 395M 346M 257M
accountPayables 9M 12M 17M 15M 19M 17M 14M 9M 11M 9M 12M 8M 9M 3M
shortTermDebt 5M 5M 0 5M 10M 5M 0 4M 4M 4M 0 4M 0 1M
taxPayables 1M 1M 7M 7M 5M 10M 11M 9M 7M 5M 4M 5M 2M 6M
deferredRevenue 0 0 0 0 5M 10M 0 0 7M 0 0 0 0 5M
otherCurrentLiabilities 46M 41M 24M 40M 32M 32M 21M 44M 32M 34M 22M 34M 22M 9M
totalCurrentLiabilities 62M 59M 70M 66M 66M 63M 65M 57M 54M 47M 52M 45M 49M 41M
longTermDebt 34M 35M 0 35M 31M 31M 0 32M 28M 28M 0 26M 0 0
deferredRevenueNonCurrent 0 0 0 0 -1 0 0 0 0 0 0 0 0 0
deferredTaxLiabilitiesNonCurrent 0 0 297 000 1M 1M 1M 1M 1M 1M 1M 1M 2M 811 000 222 000
otherNonCurrentLiabilities 7M 7M 7M 7M 5M 5M 5M 3M 3M 3M 2M 18M 9M 12M
totalNonCurrentLiabilities 41M 42M 42M 43M 37M 37M 38M 36M 33M 33M 31M 29M 38M 19M
otherLiabilities 0 0 0 0 1 0 0 0 0 0 0 0 0 0
capitalLeaseObligations 39M 41M 39M 35M 36M 31M 36M 36M 32M 32M 31M 30M 32M 9M
totalLiabilities 103M 101M 112M 109M 104M 100M 103M 93M 87M 80M 83M 75M 87M 60M
preferredStock 0 0 0 0 0 0 0 0 0 0 0 0 0 0
commonStock 497 000 495 000 493 000 493 000 492 000 491 000 488 000 488 000 485 000 483 000 482 000 482 000 477 000 464 000
retainedEarnings -130M -139M -68M -33M -43M -51M -47M -55M -64M -70M -69M -78M -111M -136M
accumulatedOtherComprehensiveIncomeLoss -7M -6M -7M -6M -5M -5M -4M -3M -3M -937 000 156 000 -310 000 -4M -6M
othertotalStockholdersEquity 490M 480M 467M 457M 448M 436M 420M 409M 398M
totalStockholdersEquity 354M 337M 397M 428M 409M 393M 386M 379M 354M 339M 336M 320M 259M 197M
totalEquity 354M 337M 397M 428M 409M 393M 386M 379M 354M 339M 336M 320M 259M 197M
totalLiabilitiesAndStockholdersEquity 456M 438M 538M 513M 493M 472M 441M 419M 395M
minorityInterest 0 0 0 0 0 0 0 0 0 0 0 0 0 0
totalLiabilitiesAndTotalEquity 456M 438M 510M 538M 513M 493M 489M 472M 441M 419M 419M 395M 346M 257M
totalInvestments 17M 23M 86M 72M 43M 28M 49M 74M 18M 13M 139M 95M 0 0
totalDebt 39M 41M 39M 40M 36M 36M 36M 36M 32M 32M 31M 30M 32M 11M
netDebt -137M -127M -105M -124M -157M -188M -147M -92M -62M -58M -55M -99M -168M -142M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link
filingDate 2025-02-21 2024-02-27 2023-02-23 2022-02-23 2021-02-24
fiscalYear 2024 2023 2022 2021 2020
accountsReceivables 78M 95M 62M 44M 35M
otherReceivables 1M 3M 4M 3M 0
prepaids 14M 4M 9M 7M 6M
totalPayables 23M 24M 15M 11M 7M
otherPayables 7M 11M 4M 2M 5M
accruedExpenses 19M 15M 11M 12M 16M
capitalLeaseObligationsCurrent 4M 4M 4M 3M 3M
capitalLeaseObligationsNonCurrent 35M 31M 27M 29M 7M
treasuryStock 0 0 0 0 0
additionalPaidInCapital 471M 437M 404M 374M 338M
otherTotalStockholdersEquity 0 0 0 0 0

Cash Flow Statement

Property 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4
date 2025-11-05 2025-06-27 2024-12-27 2024-09-27 2024-06-28 2024-03-29 2023-12-29 2023-09-29 2023-06-30 2023-03-31 2022-12-30 2022-09-30 2021-12-31 2021-01-01
symbol STAA STAA STAA STAA STAA STAA STAA STAA STAA STAA STAA STAA STAA STAA
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 718 937 718 937 718 937 718 937 718 937 718 937 718 937 718 937 718 937 718 937 718 937 718 937 718 937 718 937
fillingDate 2025-11-05 2025-08-06 2024-10-30 2024-08-07 2024-05-07 2023-11-06 2023-08-02 2023-05-03 2022-11-02
acceptedDate 2025-11-05 16:02:30 2025-08-06 16:05:55 2025-02-21 16:00:40 2024-10-30 16:08:13 2024-08-07 16:06:04 2024-05-07 16:11:10 2024-02-27 06:04:44 2023-11-06 06:05:24 2023-08-02 16:11:49 2023-05-03 16:12:08 2023-02-22 21:32:23 2022-11-02 16:11:28 2022-02-23 16:21:49 2021-02-24 16:15:59
calendarYear 2025 2025 2024 2024 2024 2023 2023 2022 2022
period Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q1 Q4 FY Q3 FY FY
netIncome 9M -17M -20M 10M 7M -3M 21M 5M 6M 3M 39M 10M 28M 6M
depreciationAndAmortization 2M 2M 7M 2M 2M 1M 5M 1M 1M 1M 5M 1M 4M 3M
deferredIncomeTax 10M -10M 4M -13 000 -1000 61 000 3M -10000 18 000 57 000 -1M 23 000 -2M -849 000
stockBasedCompensation 8M 8M 27M 7M 9M 6M 24M 9M 8M 6M 20M 6M 15M 12M
changeInWorkingCapital -31M -16M -5M 13M -30M 17M -41M -22M -25M -14M -29M 7M -2M -3M
accountsReceivables -26M 6M 16 493 -10M -29M 30M -33M -18M -31M -1M -20M 7M -9M -4M
inventory -1M -5M -10000 -1M -869 000 -4M -14M -6M -462 000 -4M -8M -2M 66 000 -1M
accountsPayables -2M 537 000 75 -6M 2M 2M -701 000 -2M 2M -3M 2M -5M 108 000 -1M
otherWorkingCapital -1M -17M -5M 30M -1M -11M 7M 4M 5M 8M -3M 8M 6M 4M
otherNonCashItems 5M 5M 4M -28M 41M -18M 2M 914 000 3M -759 000 2M -166 000 2M 3M
netCashProvidedByOperatingActivities 3M -27M 16M 4M -10M 22M 15M -6M -6M -5M 36M 24M 44M 21M
investmentsInPropertyPlantAndEquipment -883 000 -2M -23M 11M -6M -5M -18M -9M -3M -3M -18M -6M -14M -8M
acquisitionsNet 0 0 0 0 0 0 0 -41M 0 2M 138M 0 0 0
purchasesOfInvestments -12M 0 -80M -41M -20M 0 -52M -10M -15M -27M -156M 0 0 0
salesMaturitiesOfInvestments 18M 27M 44M 12M 6M 21M 145M 51M 28M 40M 17M 0 0 0
otherInvestingActivites 0 0 -18M -14M -5M 41M 0 -2M -96M
netCashUsedForInvestingActivites 5M 25M -35M -21M 16M 32M 10M 10M -102M
debtRepayment 0 0 -42 000 -42 000 -40 000 -39 000 -40 000 -42 000 -40 000
commonStockIssued 1000 12 000 2M 0 5M 7M 0 1000 0
commonStockRepurchased -2M -4M -2M 0 -167 000 -1M -2M -112 000 -135 000 -2M 0 0 0 0
dividendsPaid 0 0 0 0 0 0 0 0 0
otherFinancingActivites 3M -73 000 2M 370 000 -1M 7M 1M 529 000 5M
netCashUsedProvidedByFinancingActivities 983 000 -5M 2M 163 000 4M 7M 1M -1M 5M
effectOfForexChangesOnCash 91 000 686 000 -1M 1M -330 000 -937 000 202 000 -235 000 -441 000 10000 -862 000 -502 000 -857 000 367 000
netChangeInCash 9M -6M -39M -29M -31M 41M 97M 33M 5M 3M -113M -73M 47M 32M
cashAtEndOfPeriod 176M 167M 144M 164M 193M 224M 183M 127M 95M 90M 86M 129M 200M 152M
cashAtBeginningOfPeriod 167M 173M 183M 193M 224M 183M 86M 95M 90M 86M 200M 202M 152M 120M
operatingCashFlow 3M -27M 16M 4M -10M 22M 15M -6M -6M -5M 36M 24M 44M 21M
capitalExpenditure -883 000 -2M -23M 11M -6M -5M -18M -9M -3M -3M -18M -6M -14M -8M
freeCashFlow 2M -29M -8M 15M -17M 16M -4M -15M -9M -8M 18M 18M 30M 13M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link
filingDate 2025-02-21 2024-02-27 2023-02-23 2022-02-23 2021-02-24
fiscalYear 2024 2023 2022 2021 2020
otherInvestingActivities 0 0 -138M 0 0
netCashProvidedByInvestingActivities -59M 74M -156M -14M -8M
netDebtIssuance -165 000 -161 000 -126 000 -2M -1M
longTermNetDebtIssuance -165 000 -161 000 -126 000 -348 000 -561 000
shortTermNetDebtIssuance 0 0 0 -1M -515 000
netStockIssuance -2M -2M 1000 1000 1000
netCommonStockIssuance -2M -2M 1000 1000 1000
commonStockIssuance 2000 1000 1000 1000 1000
netPreferredStockIssuance 0 -1000 0 0 0
netDividendsPaid 0 0 0 0 0
commonDividendsPaid 0 0 0 0 0
preferredDividendsPaid 0 0 0 0 0
otherFinancingActivities 7M 10M 8M 19M 21M
netCashProvidedByFinancingActivities 6M 7M 8M 18M 20M
incomeTaxesPaid 11M 3M 7M 7M 0
interestPaid 87 000 75 000 52 000 75 000 0

Earning call transcript

2025 q1
2025-05-07 ET (fiscal 2025 q1)
2024 q4
2025-02-13 ET (fiscal 2024 q4)
2024 q3
2024-10-30 ET (fiscal 2024 q3)
2024 q2
2024-08-09 ET (fiscal 2024 q2)
2024 q1
2024-05-07 ET (fiscal 2024 q1)
2023 q4
2024-02-26 ET (fiscal 2023 q4)
2023 q3
2023-11-01 ET (fiscal 2023 q3)
2023 q2
2023-08-02 ET (fiscal 2023 q2)
2023 q1
2023-05-03 ET (fiscal 2023 q1)
2022 q4
2023-02-21 ET (fiscal 2022 q4)
2022 q3
2022-11-03 ET (fiscal 2022 q3)
2022 q2
2022-08-10 ET (fiscal 2022 q2)
2022 q1
2022-05-04 ET (fiscal 2022 q1)

Press-releases

Show financial reports only

2026-05-13 20:01 ET
STAAR Surgical Reports First Quarter 2026 Results; Issues Shareholder Letter
2026-05-04 20:01 ET
STAAR Surgical to Host First Quarter 2026 Earnings Results Call and Webcast on May 13, 2026
2026-04-08 ET
STAAR Surgical Announces Preliminary Net Sales for First Quarter 2026
2026-03-03 ET
STAAR Surgical Issues Shareholder Letter
2026-03-03 ET
STAAR Surgical Reports Fourth Quarter and Fiscal Year 2025 Results
2026-02-25 ET
STAAR Surgical Surpasses 4 Million ICLs Sold Globally, Reflecting Ongoing Shift Away from Laser-Based Vision Correction
2026-02-23 ET
STAAR Surgical to Host Fourth Quarter and Fiscal Year 2025 Earnings Conference Call and Webcast on March 3, 2026
2026-02-17 21:01 ET
FDA Expands U.S. Age Indication for EVO ICL as Long-Term Safety Data Reinforces Market Shift Away From Laser Vision Correction
2026-02-02 ET
STAAR Surgical Appoints Warren Foust and Deborah Andrews Interim Co-CEOs
2026-01-15 ET
STAAR Surgical and Broadwood Partners Enter Into Cooperation Agreement
2026-01-06 ET
Alcon Terminates Agreement to Acquire STAAR Surgical
2026-01-06 ET
Broadwood Partners Comments on STAAR Surgical Shareholders’ Rejection of the Company’s Proposed Sale to Alcon
2026-01-06 ET
STAAR Surgical Announces Preliminary Results of Special Meeting of Stockholders
2025-12-19 ET
Broadwood Partners Denounces STAAR Surgical’s Fourth Delay of the Shareholder Vote on the Company’s Proposed Sale to Alcon
2025-12-19 ET
Alcon Exercises Right to Require STAAR Surgical to Adjourn its Special Meeting of Stockholders
2025-12-17 ET
Defender Capital Reiterates Intention to Vote AGAINST STAAR Surgical's Proposed Sale to Alcon Inc.
2025-12-17 ET
Broadwood Partners Issues Open Letter to STAAR Surgical Board Pledging Cooperation and Support When Vote on Alcon Transaction Fails
2025-12-17 ET
STAAR Stockholders Have a Choice: Vote FOR Alcon’s Certain, Premium $30.75 Per Share Cash Offer or Bear the Downside Risk that Broadwood Has No Credible Plan to Create Stockholder Value
2025-12-16 ET
Yunqi Capital Comments on Proxy Advisors’ Updated Recommendations, Urges Shareholders to Continue to Back the Company’s Standalone Trajectory
2025-12-16 ET
Independent Industry Analysts Recognize Value Provided to STAAR Stockholders by Amended Alcon Merger Agreement and Merits of Alcon Transaction
2025-12-16 ET
Broadwood Partners Comments on ISS Report on Proposed Sale of STAAR Surgical to Alcon
2025-12-15 ET
Leading Independent Proxy Advisory Firm ISS Recommends STAAR Stockholders Vote “FOR” Alcon Merger
2025-12-12 ET
Broadwood Partners: Leading Proxy Advisory Firm Glass Lewis Reaffirms Recommendation “AGAINST” STAAR Surgical Sale to Alcon
2025-12-11 ET
STAAR Surgical Sets the Record Straight Regarding its Robust Go-Shop Process
2025-12-11 ET
Broadwood Partners Comments on STAAR Surgical Board Dissent on the Revised Sale to Alcon
2025-12-10 ET
Yunqi Capital Comments on STAAR Surgical’s Go-Shop Process and Alcon’s Revised Offer
2025-12-09 ET
Broadwood Partners Responds to Alcon’s Increase to Proposed Acquisition Price of STAAR Surgical
2025-12-09 ET
Alcon Announces Amended Merger Agreement with STAAR Surgical
2025-12-08 ET
Broadwood Partners Reiterates Opposition to STAAR Surgical’s Sale to Alcon Following Conclusion of Performative Go-Shop Process
2025-12-08 ET
Broadwood Partners: Proxy Advisory Firm Egan-Jones Reaffirms Its Recommendation STAAR Surgical Shareholders Vote “AGAINST” Sale to Alcon
2025-12-08 ET
STAAR Surgical Announces Expiration of Go-Shop Period
2025-12-02 ET
Broadwood Partners Working to Call Special Meeting of STAAR Surgical Shareholders to Remove Three Directors
2025-11-07 ET
STAAR Surgical Announces Amendments to Alcon Merger Agreement
2025-11-06 ET
Yunqi Capital Applauds STAAR Surgical’s Strong Third Quarter Results and Reiterates That the Proposed Sale to Alcon Should Be Terminated
2025-11-05 ET
STAAR Surgical Reports Third Quarter 2025 Results
2025-11-04 ET
Broadwood Partners Condemns Alcon’s Fallacious Attacks on STAAR Surgical and Its Prospects
2025-11-04 ET
Alcon Releases Investor Discussion Materials Reinforcing Certain Value of Merger Proposal for STAAR Stockholders
2025-10-31 ET
Yunqi Capital Issues Letter to STAAR Surgical Board Calling for Termination of the Proposed Merger with Alcon
2025-10-27 ET
STAAR Surgical Sets New Record Date and Postpones STAAR Special Meeting of Stockholders in Light of Ongoing Discussions with Alcon
2025-10-24 ET
Yunqi Capital Issues Letter to STAAR Surgical Board Opposing Adjournment of the Special Meeting and Calling for the Company to Move Beyond the Proposed Merger with Alcon
2025-10-24 ET
Broadwood Partners Condemns Decision by STAAR Surgical and Alcon to Delay Final Vote on Proposed Transaction
2025-10-23 ET
Alcon and STAAR Surgical Announce Adjournment of STAAR Special Meeting of Stockholders
2025-10-22 ET
Broadwood Partners Intends to Call Special Meeting to Remove Several STAAR Surgical Directors
2025-10-20 ET
Yunqi Capital Issues Letter to STAAR Surgical’s Board Calling for Timely Convening of the Special Meeting to Vote on the Alcon Transaction
2025-10-20 ET
Broadwood Partners Highlights Growing Opposition to STAAR Surgical’s Proposed Sale to Alcon
2025-10-20 ET
STAAR Surgical Announces Preliminary Net Sales Results for Third Quarter 2025
2025-10-17 ET
Broadwood Partners Issues Letter to STAAR Surgical’s Board Urging it to Allow Timely Shareholder Vote on Alcon Sale
2025-10-16 ET
STAAR Surgical Affirms that No Acquisition Proposals Have Been Received From Any Party Other Than Alcon
2025-10-15 ET
Broadwood Partners: All Three Leading Proxy Advisory Firms Recommend STAAR Surgical Shareholders Vote “AGAINST” Sale to Alcon
2025-10-14 ET
Broadwood Partners Comments on STAAR Surgical’s Late and Troubling Disclosure in Deeply Flawed Sale Process to Alcon
2025-10-10 ET
Broadwood Partners Issues Letter to STAAR Surgical’s Board Questioning Its Diligence in Rush to Reaffirm Support for Alcon Sale
2025-10-08 ET
STAAR Surgical Board of Directors Reiterates Unanimous Recommendation that STAAR Stockholders Vote “FOR” the Alcon Merger Agreement on WHITE Proxy Card
2025-10-08 ET
Broadwood Partners: Leading Advisory Firm Glass Lewis Urges STAAR Shareholders to Vote “AGAINST” Sale to Alcon
2025-10-08 ET
Broadwood Partners Questions Integrity of STAAR Surgical’s Last-Minute Forecast Change and Fairness Opinion in Sale to Alcon
2025-10-07 ET
Defender Capital Opposes STAAR Surgical's Proposed Sale to Alcon
2025-10-06 ET
Yunqi Capital, One of STAAR Surgical Company’s Largest Shareholders, Reiterates Its Opposition to the Proposed Merger with Alcon
2025-10-06 ET
Broadwood Partners Issues Letter to STAAR Surgical’s Board Questioning Its Judgment in Proposed Sale to Alcon
2025-10-06 ET
STAAR Surgical: Independent Industry Analysts Recognize Merits of Alcon Merger, the Value It Provides, and the Downside Risks Facing STAAR on Standalone Basis
2025-10-06 ET
STAAR Surgical Addresses Broadwood Partners’ Flawed, Misleading, and Misinformed Claims
2025-10-03 ET
Broadwood Partners Publishes Presentation Detailing Opposition to STAAR Surgical’s Sale to Alcon
2025-09-30 ET
Alcon and STAAR Surgical Announce Expiration of Hart-Scott-Rodino Waiting Period for Alcon’s Acquisition of STAAR
2025-09-26 ET
STAAR Surgical Publishes Presentation Highlighting Compelling, Certain Cash Value Offered by Alcon Merger and Meaningful Downside Risks if Alcon Merger is not Approved
2025-09-02 ET
STAAR Surgical Reiterates Compelling, Premium Cash Value Provided by Alcon Merger
2025-08-05 ET
STAA Alert: Monsey Firm of Wohl & Fruchter Investigating Fairness of the Sale of STAAR Surgical to Alcon
2025-07-31 ET
STAAR Surgical to Host Second Quarter 2025 Earnings Conference Call and Webcast on August 6, 2025
2025-06-25 ET
STAAR Surgical Announces Appointment of Deborah Andrews as Chief Financial Officer, Forms Capital Stewardship Committee of the Board of Directors
2025-05-22 ET
STAAR Surgical Announces Participation in Upcoming Investor Conferences
2025-05-16 ET
STAAR Surgical Announces $30 Million Share Repurchase Authorization
2025-05-07 ET
STAAR Surgical Reports First Quarter 2025 Results
2025-04-24 ET
STAAR Surgical Announces Changes to Board of Directors
2025-04-23 ET
STAAR Surgical to Host First Quarter 2025 Earnings Conference Call and Webcast on May 7, 2025
2025-03-17 ET
STAAR Surgical Announces Realignment of Leadership Structure
2025-02-26 ET
STAAR Surgical Announces Leadership Transition
2025-02-11 ET
STAAR Surgical Reports Fourth Quarter and Fiscal Year 2024 Results
2025-01-13 ET
STAAR Surgical to Host Fourth Quarter and Fiscal Year 2024 Earnings Conference Call and Webcast on February 19, 2025
2024-11-25 ET
STAAR Surgical to Participate in BTIG Ophthalmology Day
2024-11-13 ET
STAAR Surgical to Participate in Stephens Annual Investment Conference (NASH2024)
2024-10-30 20:01 ET
STAAR Surgical Reports Third Quarter 2024 Results
2024-10-30 20:01 ET
CORRECTING and REPLACING STAAR Surgical Reports Third Quarter 2024 Results
2024-10-23 11:00 ET
STAAR Surgical to Report Third Quarter Results on October 30, 2024
2024-09-23 11:00 ET
STAAR Surgical Experience Center Expands to Meet Growing Surgeon Demand
2024-08-07 20:01 ET
STAAR Surgical Reports Second Quarter 2024 Results
2024-07-31 11:00 ET
STAAR Surgical to Report Second Quarter Results on August 7, 2024
2024-07-30 11:00 ET
STAAR Surgical to Participate in Canaccord Genuity 44th Annual Growth Conference
2024-06-05 11:00 ET
STAAR Surgical to Participate in Goldman Sachs 45th Annual Global Healthcare Conference
2024-05-07 20:03 ET
STAAR Surgical Reports First Quarter 2024 Results
2024-05-07 20:01 ET
STAAR Surgical Announces Milestone Strategic Agreement in U.S. with IQ Laser Vision
2024-05-01 11:00 ET
STAAR Surgical Strengthens Leadership Team with Appointments of Nancy Sabin as Chief Marketing Officer and Nathaniel Sisitsky as General Counsel
2024-04-29 11:00 ET
STAAR Surgical to Report First Quarter Results on May 7, 2024
2024-04-04 11:00 ET
STAAR Surgical Announces Preliminary Net Sales for First Quarter 2024
2024-04-02 11:00 ET
STAAR Surgical Celebrates Three Million Lens Milestone at ASCRS Meeting, Unveils New EVO ICL Data and Latest Innovation for 2024
2024-03-18 11:00 ET
STAAR Surgical Celebrates Three Million Implantable Collamer® Lenses
2024-03-12 11:00 ET
STAAR Surgical Adds Arthur Butcher and Wei Jiang to Board of Directors
2024-03-06 12:00 ET
STAAR Surgical to Participate in Two Upcoming Investor Conferences
2024-02-26 21:01 ET
STAAR Surgical Reports Fourth Quarter and Fiscal Year 2023 Results
2024-02-19 12:00 ET
STAAR Surgical to Report Fourth Quarter Results on February 26, 2024
2024-01-23 12:00 ET
STAAR Surgical Announces Strategic Agreement in U.S. with SharpeVision
2024-01-08 12:00 ET
STAAR Surgical Announces Preliminary Results for Fourth Quarter and Fiscal 2023
2023-12-04 21:05 ET
Lilian Zhou Appointed to STAAR Surgical Board of Directors
2023-11-15 12:00 ET
STAAR Surgical to Present at Stephens Annual Investment Conference (NASH2023)
2023-11-01 20:01 ET
STAAR Surgical Reports Third Quarter 2023 Results
2023-10-18 20:05 ET
STAAR Surgical to Report Third Quarter Results on November 1, 2023
2023-10-17 11:00 ET
STAAR Surgical Celebrates 30th Anniversary of Implantable Collamer® Lens (ICL)
2023-10-10 14:51 ET
Jimmy O. Yang Partners with STAAR Surgical to Shine a Light on Their Vision Correction Lens, EVO ICL
2023-09-14 11:00 ET
STAAR Surgical to Ring Nasdaq Stock Market Closing Bell Following Vision 2026 Investor Day on September 14, 2023
2023-09-07 21:00 ET
STAAR Surgical to Host “Vision 2026” Investor Day on September 14, 2023
2023-08-17 22:48 ET
Dolby Laboratories Set to Join S&P MidCap 400; Staar Surgical to Join S&P SmallCap 600
2023-08-09 11:00 ET
STAAR Surgical Teams Up With Tennessee Titans Quarterback Will Levis On Life Changing Vision Correction Procedure, EVO ICL
2023-08-07 11:00 ET
STAAR Surgical to Participate in Upcoming Investor Conferences
2023-08-02 20:01 ET
STAAR Surgical Reports Second Quarter 2023 Results
2023-07-19 11:00 ET
STAAR Surgical to Report Second Quarter Results on August 2, 2023
2023-05-04 11:00 ET
EVO ICL Sponsors Jonas Brothers’ The Tour
2023-05-03 20:01 ET
STAAR Surgical Reports First Quarter 2023 Results
2023-04-19 11:00 ET
STAAR Surgical to Report First Quarter Results on May 3, 2023
2023-03-29 11:00 ET
STAAR Surgical Names Warren Foust Chief Operating Officer; Magda Michna, Ph.D., Chief Clinical, Regulatory and Medical Affairs Officer
2023-02-21 21:01 ET
STAAR Surgical Reports Fourth Quarter and Fiscal Year 2022 Results
2023-02-07 12:00 ET
STAAR Surgical to Report Fourth Quarter and Fiscal Year Results on February 21, 2023
2023-01-11 12:00 ET
Actress and Beauty Entrepreneur Peyton List Sets Her Sights on 2023 with Upgraded Vision from Life-Changing EVO ICL Lenses
2023-01-09 12:00 ET
STAAR Surgical Reports Preliminary Sales for Fourth Quarter and Fiscal 2022
2022-12-19 13:15 ET
STAAR Surgical CEO Caren Mason to Retire; Tom Frinzi Appointed New CEO
2022-11-17 12:00 ET
STAAR Surgical Opens EVO Experience Center in United States
2022-11-02 20:01 ET
STAAR Surgical Reports Third Quarter Net Sales of $76 Million Up 30% Y/Y
2022-10-19 11:00 ET
STAAR Surgical to Report Third Quarter Results on November 2, 2022
2022-10-12 11:00 ET
Professional Basketball Player Max Strus Kicks Off New Season With Upgraded Vision From Life-Changing EVO ICL Lenses
2022-09-14 11:00 ET
STAAR Surgical Patient Awareness Campaign Launched In New York
2022-08-10 20:03 ET
STAAR Surgical and Joe Jonas Team Up to Introduce New Life-Changing EVO ICL to Millions of Americans Suffering from Distance Vision Problems
2022-08-10 20:01 ET
STAAR Surgical Reports Record Second Quarter Net Sales of $81.1 Million Up 30% Y/Y
2022-07-20 11:00 ET
STAAR Surgical to Report Second Quarter Results on August 10, 2022
2022-06-07 11:00 ET
STAAR Surgical Celebrates Two Million Lens Milestone for Implantable Collamer® Lens (ICL)
2022-05-04 20:01 ET
STAAR Surgical Reports Record First Quarter Net Sales of $63.2 Million Up 25% Y/Y
2022-04-20 11:00 ET
STAAR Surgical to Report First Quarter Results on May 4, 2022
2022-04-06 11:00 ET
STAAR Surgical Announces First Implants of EVO Visian ICL in the U.S.
2022-03-28 07:01 ET
STAAR Surgical Announces U.S. FDA Approval of EVO Visian® Implantable Collamer® Lenses
2022-02-23 21:01 ET
STAAR Surgical Reports Fourth Quarter and Full Year 2021 Results
2022-02-09 12:00 ET
STAAR Surgical to Report Fourth Quarter and Fiscal Year Results on February 23, 2022
2022-01-10 12:00 ET
STAAR Surgical Announces Preliminary Fourth Quarter and Full Year 2021 Results
2021-11-03 20:01 ET
STAAR Surgical Reports Third Quarter Net Sales of $58.4 Million Up 24% Y/Y
2021-10-20 11:00 ET
STAAR Surgical to Report Third Quarter Results on November 3, 2021
2021-08-04 20:01 ET
STAAR Surgical Reports Record Second Quarter Net Sales of $62.4 Million Up 77% Y/Y and Increases Outlook for 2021
2021-07-21 13:15 ET
STAAR Surgical to Report Second Quarter Results on August 4, 2021
2021-05-05 20:01 ET
STAAR Surgical Reports Record First Quarter 2021 Net Sales of $50.8 Million Up 44% Y/Y
2021-04-21 11:00 ET
STAAR Surgical to Report First Quarter Results on May 5, 2021
2021-02-24 21:01 ET
STAAR Surgical Reports Fourth Quarter and Full Year 2020 Results
2021-02-10 12:00 ET
STAAR Surgical to Report Fourth Quarter and Fiscal Year Results on February 24, 2021
2021-01-26 15:45 ET
Elizabeth Yeu, M.D. and K. Peony Yu, M.D. Appointed to STAAR Surgical Board of Directors
2021-01-25 23:35 ET
Staar Surgical Set to Join S&P MidCap 400; Prestige Consumer Healthcare & Bridge Bancorp to Join S&P SmallCap 600
2021-01-10 23:00 ET
STAAR Surgical Announces Preliminary Fourth Quarter and Full Year 2020 Results
2020-11-04 21:03 ET
STAAR Surgical Begins Commercialization of EVO Viva™ Presbyopia Correcting Lens
2020-11-04 21:01 ET
STAAR Surgical Reports Third Quarter 2020 Results
2020-10-21 11:00 ET
STAAR Surgical to Report Third Quarter Results on November 4, 2020
2020-10-02 13:00 ET
Notice of Lead Plaintiff Deadline for Shareholders in the STAAR Surgical Company Class Action Lawsuit
2020-09-16 14:28 ET
STAA INVESTOR FILING DEADLINE: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Against Staar Surgical Company
2020-09-14 11:00 ET
STAAR Surgical Announces Completion of Patient Enrollment in EVO Implantable Lens US Clinical Trial
2020-09-02 11:00 ET
STAAR Surgical to Participate in Upcoming Investor Conferences
2020-08-24 13:00 ET
Notice of Lead Plaintiff Deadline for Shareholders in the STAAR Surgical Company Class Action Lawsuit
2020-08-05 20:01 ET
STAAR Surgical Reports Second Quarter 2020 Results
2020-07-22 11:00 ET
STAAR Surgical to Report Second Quarter Results on August 5, 2020
2020-07-14 11:00 ET
STAAR Surgical Company to Hold 2020 Annual Meeting of Shareholders in Virtual Format
2020-07-07 11:00 ET
STAAR Surgical Introduces EVO Viva™ Presbyopia Correcting Lens – See Young Again!
2020-07-06 11:00 ET
Patrick F. Williams Appointed Chief Financial Officer of STAAR Surgical
2020-06-01 11:00 ET
Dr. Gil Kliman and Tom Frinzi Appointed to STAAR Surgical Board of Directors
2020-05-06 20:01 ET
STAAR Surgical Reports First Quarter 2020 Results
2020-04-15 11:00 ET
STAAR Surgical to Report First Quarter Results on May 6, 2020
2020-04-13 11:00 ET
STAAR Surgical Provides COVID-19 Business Update
2020-02-26 21:01 ET
STAAR Surgical Reports Fourth Quarter and Full Year 2019 Results
2020-02-05 12:05 ET
STAAR Surgical to Report Fourth Quarter and Fiscal Year Results on February 26, 2020
2020-02-05 12:00 ET
STAAR Surgical Announces Strategic Cooperation Agreement with Senshinkai Eye Institute, A Leading Eye Care Chain in Japan
2020-02-04 12:00 ET
STAAR Surgical Announces the EVO Implantable Lens US Clinical Trial is Underway with 1st Patient Implanted at Price Vision Group in Indianapolis on January 30th
2019-12-18 21:05 ET
STAAR CFO to Retire in 2020
2019-12-17 12:00 ET
STAAR Surgical Announces Strategic Alliance Agreement with California Center for Refractive Surgery (CCRS)
2019-12-11 12:00 ET
STAAR Surgical Announces FDA IDE Clinical Study Approval
2019-11-06 12:00 ET
STAAR Surgical to Host Investor and Analyst Day on November 8, 2019
2019-10-30 20:01 ET
STAAR Surgical Reports Third Quarter Results
2019-10-09 11:01 ET
STAAR Surgical Celebrates Visual Freedom with Jorgensen Family
2019-10-09 11:00 ET
STAAR Surgical to Report Third Quarter Results on October 30, 2019
2019-09-09 11:00 ET
STAAR Surgical Announces EVO ICL Clinical Program for Its 16th Annual Surgical Experts Summit in Paris, France From September 11 – 13, 2019
2019-07-31 20:10 ET
STAAR Surgical Announces Submission of Presbyopia Clinical Trial Data; Proprietary EDOF Collamer® Lens is Designed to Improve Near, Intermediate and Distance Vision
2019-07-31 20:01 ET
STAAR Surgical Reports Record Second Quarter Results for Total Revenue, ICL Sales and ICL Units

SEC forms

Show financial reports only

SEC form 10
2026-05-13 20:06 ET
STAAR Surgical Co published news for 2026 q1
SEC form 8
2026-05-13 20:02 ET
STAAR Surgical Co published news for 2026 q1
SEC form 8
2026-05-13 20:02 ET
STAAR Surgical Co published news for 2026 q1
SEC form 8
2026-04-08 20:05 ET
STAAR Surgical Co published news for 2026 q1
SEC form 8
2026-04-08 20:05 ET
STAAR Surgical Co published news for 2026 q1
SEC form 8
2026-03-03 16:05 ET
STAAR Surgical Co published news for 2025 q4
SEC form 8
2026-03-03 16:05 ET
STAAR Surgical Co published news for 2025 q4
SEC form 8
2026-03-03 16:05 ET
STAAR Surgical Co published news for 2025 q4
SEC form 10
2026-03-03 15:58 ET
STAAR Surgical Co published news for 2025 q4
SEC form 8
2026-01-06 14:01 ET
STAAR Surgical Co published news for 2025 q4
SEC form 8
2026-01-06 14:01 ET
STAAR Surgical Co published news for 2025 q4
SEC form 8
2025-12-09 13:30 ET
STAAR Surgical Co published news for 2025 q3
SEC form 8
2025-12-09 13:30 ET
STAAR Surgical Co published news for 2025 q3
SEC form 8
2025-12-08 13:13 ET
STAAR Surgical Co published news for 2025 q3
SEC form 8
2025-12-08 13:13 ET
STAAR Surgical Co published news for 2025 q3
SEC form 8
2025-11-07 12:39 ET
STAAR Surgical Co published news for 2025 q3
SEC form 8
2025-11-07 12:39 ET
STAAR Surgical Co published news for 2025 q3
SEC form 8
2025-11-07 12:39 ET
STAAR Surgical Co published news for 2025 q3
SEC form 10
2025-11-05 21:06 ET
STAAR Surgical Co reported for 2025 q3
SEC form 8
2025-11-05 21:02 ET
STAAR Surgical Co published news for 2025 q3
SEC form 8
2025-11-05 21:02 ET
STAAR Surgical Co published news for 2025 q3
SEC form 8
2025-10-27 14:52 ET
STAAR Surgical Co published news for 2025 q3
SEC form 8
2025-10-27 14:52 ET
STAAR Surgical Co published news for 2025 q3
SEC form 8
2025-10-23 20:21 ET
STAAR Surgical Co published news for 2025 q3
SEC form 8
2025-10-23 20:21 ET
STAAR Surgical Co published news for 2025 q3
SEC form 8
2025-10-20 11:45 ET
STAAR Surgical Co published news for 2025 q3
SEC form 8
2025-10-20 11:45 ET
STAAR Surgical Co published news for 2025 q3
SEC form 8
2025-09-26 13:14 ET
STAAR Surgical Co published news for 2025 q2
SEC form 8
2025-09-26 13:14 ET
STAAR Surgical Co published news for 2025 q2
SEC form 8
2025-09-26 13:14 ET
STAAR Surgical Co published news for 2025 q2
SEC form 10
2025-08-06 20:05 ET
STAAR Surgical Co reported for 2025 q2
SEC form 8
2025-08-06 20:02 ET
STAAR Surgical Co published news for 2025 q2
SEC form 8
2025-08-06 20:02 ET
STAAR Surgical Co published news for 2025 q2
SEC form 8
2025-08-05 12:37 ET
STAAR Surgical Co published news for 2025 q2
SEC form 8
2025-08-05 12:37 ET
STAAR Surgical Co published news for 2025 q2
SEC form 8
2025-08-05 12:37 ET
STAAR Surgical Co published news for 2025 q2
SEC form 8
2025-06-04 11:00 ET
STAAR Surgical Co published news for 2025 q1
SEC form 8
2025-06-04 11:00 ET
STAAR Surgical Co published news for 2025 q1
SEC form 8
2025-05-16 11:00 ET
STAAR Surgical Co published news for 2025 q1
SEC form 8
2025-05-16 11:00 ET
STAAR Surgical Co published news for 2025 q1
SEC form 10
2025-05-07 20:11 ET
STAAR Surgical Co reported for 2025 q1
SEC form 8
2025-05-07 20:02 ET
STAAR Surgical Co published news for 2025 q1
SEC form 8
2025-05-07 20:02 ET
STAAR Surgical Co reported for 2025 q1
SEC form 8
2025-05-07 20:02 ET
STAAR Surgical Co published news for 2025 q1
SEC form 10
2025-05-07 00:00 ET
STAAR Surgical Co reported for 2025 q1
SEC form 10
2025-02-21 21:00 ET
STAAR Surgical Co published news for 2024 q4
SEC form 10
2025-02-21 00:00 ET
STAAR Surgical Co published news for 2024 q4
SEC form 8
2025-02-11 00:00 ET
STAAR Surgical Co published news for 2024 q4
SEC form 8
2025-02-11 00:00 ET
STAAR Surgical Co reported for 2024 q4
SEC form 8
2025-02-11 00:00 ET
STAAR Surgical Co published news for 2024 q4
SEC form 8
2024-10-31 06:04 ET
STAAR Surgical Co published news for 2024 q3
SEC form 8
2024-10-31 06:04 ET
STAAR Surgical Co published news for 2024 q3
SEC form 8
2024-10-31 06:04 ET
STAAR Surgical Co published news for 2024 q3
SEC form 10
2024-10-30 16:08 ET
STAAR Surgical Co reported for 2024 q3
SEC form 10
2024-10-30 00:00 ET
STAAR Surgical Co published news for 2024 q3
SEC form 8
2024-10-30 00:00 ET
STAAR Surgical Co published news for 2024 q3
SEC form 8
2024-10-30 00:00 ET
STAAR Surgical Co published news for 2024 q3
SEC form 8
2024-10-30 00:00 ET
STAAR Surgical Co published news for 2024 q3
SEC form 10
2024-08-07 16:06 ET
STAAR Surgical Co reported for 2024 q2
SEC form 8
2024-08-07 16:03 ET
STAAR Surgical Co published news for 2024 q2
SEC form 8
2024-08-07 16:03 ET
STAAR Surgical Co published news for 2024 q2
SEC form 8
2024-08-07 16:03 ET
STAAR Surgical Co published news for 2024 q2
SEC form 10
2024-08-07 00:00 ET
STAAR Surgical Co published news for 2024 q2
SEC form 10
2024-05-07 16:11 ET
STAAR Surgical Co reported for 2024 q1
SEC form 8
2024-05-07 16:03 ET
STAAR Surgical Co published news for 2024 q1
SEC form 8
2024-05-07 16:03 ET
STAAR Surgical Co reported for 2024 q1
SEC form 8
2024-05-07 16:03 ET
STAAR Surgical Co published news for 2024 q1
SEC form 10
2024-05-07 00:00 ET
STAAR Surgical Co published news for 2024 q1
SEC form 8
2024-04-04 00:00 ET
STAAR Surgical Co published news for 2024 q1
SEC form 8
2024-04-04 00:00 ET
STAAR Surgical Co published news for 2024 q1
SEC form 10
2024-02-27 06:04 ET
STAAR Surgical Co published news for 2023 q4
SEC form 10
2024-02-27 00:00 ET
STAAR Surgical Co published news for 2023 q4
SEC form 8
2024-02-26 16:04 ET
STAAR Surgical Co published news for 2023 q4
SEC form 8
2024-02-26 16:04 ET
STAAR Surgical Co reported for 2023 q4
SEC form 8
2024-01-08 00:00 ET
STAAR Surgical Co published news for 2023 q4
SEC form 8
2024-01-08 00:00 ET
STAAR Surgical Co published news for 2023 q4
SEC form 8
2024-01-08 00:00 ET
STAAR Surgical Co published news for 2023 q4
SEC form 10
2023-11-06 00:00 ET
STAAR Surgical Co published news for 2023 q3
SEC form 8
2023-11-01 16:11 ET
STAAR Surgical Co reported for 2023 q3
SEC form 6
2023-08-03 16:42 ET
STAAR Surgical Co published news for 2023 q2
SEC form 10
2023-08-02 16:11 ET
STAAR Surgical Co reported for 2023 q2
SEC form 6
2023-08-02 16:06 ET
STAAR Surgical Co published news for 2023 q2
SEC form 10
2023-08-02 00:00 ET
STAAR Surgical Co published news for 2023 q2
SEC form 8
2023-08-02 00:00 ET
STAAR Surgical Co published news for 2023 q2
SEC form 6
2023-06-16 17:14 ET
STAAR Surgical Co published news for 2023 q1
SEC form 6
2023-06-07 16:07 ET
STAAR Surgical Co published news for 2023 q1
SEC form 6
2023-06-06 06:59 ET
STAAR Surgical Co published news for 2023 q1
SEC form 10
2023-05-03 00:00 ET
STAAR Surgical Co published news for 2023 q1
SEC form 8
2023-05-03 00:00 ET
STAAR Surgical Co published news for 2023 q1
SEC form 6
2023-03-29 07:00 ET
STAAR Surgical Co published news for 2022 q4
SEC form 6
2023-03-14 10:45 ET
STAAR Surgical Co published news for 2022 q4
SEC form 10
2023-02-23 00:00 ET
STAAR Surgical Co reported for 2022 q4
SEC form 10
2023-02-22 21:32 ET
STAAR Surgical Co reported for 2022 q4
SEC form 6
2023-02-22 20:06 ET
STAAR Surgical Co published news for 2022 q4
SEC form 6
2023-02-21 16:06 ET
STAAR Surgical Co published news for 2022 q4
SEC form 8
2023-02-21 00:00 ET
STAAR Surgical Co reported for 2022 q4
SEC form 6
2023-02-01 16:30 ET
STAAR Surgical Co published news for 2022 q4
SEC form 6
2023-01-09 08:00 ET
STAAR Surgical Co published news for 2022 q4
SEC form 8
2023-01-09 00:00 ET
STAAR Surgical Co published news for 2022 q4
SEC form 6
2022-12-19 06:05 ET
STAAR Surgical Co published news for 2022 q3
SEC form 6
2022-11-03 16:06 ET
STAAR Surgical Co published news for 2022 q3
SEC form 10
2022-11-02 16:11 ET
STAAR Surgical Co reported for 2022 q3
SEC form 6
2022-11-02 16:06 ET
STAAR Surgical Co published news for 2022 q3
SEC form 10
2022-11-02 00:00 ET
STAAR Surgical Co reported for 2022 q3
SEC form 8
2022-11-02 00:00 ET
STAAR Surgical Co reported for 2022 q3
SEC form 6
2022-08-11 16:07 ET
STAAR Surgical Co published news for 2022 q2
SEC form 10
2022-08-10 16:15 ET
STAAR Surgical Co reported for 2022 q2
SEC form 6
2022-08-10 16:10 ET
STAAR Surgical Co published news for 2022 q2
SEC form 10
2022-08-10 00:00 ET
STAAR Surgical Co reported for 2022 q2
SEC form 8
2022-08-10 00:00 ET
STAAR Surgical Co reported for 2022 q2
SEC form 6
2022-07-20 17:00 ET
STAAR Surgical Co published news for 2022 q2
SEC form 6
2022-06-17 16:27 ET
STAAR Surgical Co published news for 2022 q1
SEC form 6
2022-06-07 08:00 ET
STAAR Surgical Co published news for 2022 q1
SEC form 6
2022-05-05 19:44 ET
STAAR Surgical Co published news for 2022 q1
SEC form 10
2022-05-04 16:14 ET
STAAR Surgical Co reported for 2022 q1
SEC form 6
2022-05-04 16:12 ET
STAAR Surgical Co published news for 2022 q1
SEC form 10
2022-05-04 00:00 ET
STAAR Surgical Co reported for 2022 q1
SEC form 8
2022-05-04 00:00 ET
STAAR Surgical Co reported for 2022 q1
SEC form 6
2022-04-29 16:33 ET
STAAR Surgical Co published news for 2022 q1
SEC form 6
2022-04-13 16:34 ET
STAAR Surgical Co published news for 2022 q1
SEC form 6
2022-04-06 08:00 ET
STAAR Surgical Co published news for 2022 q1
SEC form 6
2022-03-28 08:01 ET
STAAR Surgical Co published news for 2021 q4
SEC form 6
2022-02-24 16:06 ET
STAAR Surgical Co published news for 2021 q4
SEC form 6
2022-02-23 17:22 ET
STAAR Surgical Co published news for 2021 q4
SEC form 10
2022-02-23 16:21 ET
STAAR Surgical Co published news for 2021 q4
SEC form 10
2022-02-23 00:00 ET
STAAR Surgical Co published news for 2021 q4
SEC form 8
2022-02-23 00:00 ET
STAAR Surgical Co published news for 2021 q4
SEC form 6
2022-02-01 08:46 ET
STAAR Surgical Co published news for 2021 q4
SEC form 6
2022-01-10 09:01 ET
STAAR Surgical Co published news for 2021 q4
SEC form 8
2022-01-10 00:00 ET
STAAR Surgical Co published news for 2021 q4
SEC form 6
2021-11-04 17:00 ET
STAAR Surgical Co published news for 2021 q3
SEC form 10
2021-11-03 16:16 ET
STAAR Surgical Co published news for 2021 q3
SEC form 6
2021-11-03 16:11 ET
STAAR Surgical Co published news for 2021 q3
SEC form 10
2021-11-03 00:00 ET
STAAR Surgical Co published news for 2021 q3
SEC form 8
2021-11-03 00:00 ET
STAAR Surgical Co published news for 2021 q3
SEC form 6
2021-09-24 16:05 ET
STAAR Surgical Co published news for 2021 q2
SEC form 6
2021-08-09 20:22 ET
STAAR Surgical Co published news for 2021 q2
SEC form 6
2021-08-05 16:12 ET
STAAR Surgical Co published news for 2021 q2
SEC form 10
2021-08-04 16:13 ET
STAAR Surgical Co published news for 2021 q2
SEC form 6
2021-08-04 16:10 ET
STAAR Surgical Co published news for 2021 q2
SEC form 10
2021-08-04 00:00 ET
STAAR Surgical Co published news for 2021 q2
SEC form 8
2021-08-04 00:00 ET
STAAR Surgical Co published news for 2021 q2
SEC form 6
2021-06-25 16:06 ET
STAAR Surgical Co published news for 2021 q1
SEC form 6
2021-05-26 18:08 ET
STAAR Surgical Co published news for 2021 q1
SEC form 6
2021-05-06 16:25 ET
STAAR Surgical Co published news for 2021 q1
SEC form 10
2021-05-05 16:11 ET
STAAR Surgical Co published news for 2021 q1
SEC form 6
2021-05-05 16:06 ET
STAAR Surgical Co published news for 2021 q1
SEC form 10
2021-05-05 00:00 ET
STAAR Surgical Co published news for 2021 q1
SEC form 8
2021-05-05 00:00 ET
STAAR Surgical Co published news for 2021 q1
SEC form 6
2021-04-30 08:01 ET
STAAR Surgical Co published news for 2021 q1
SEC form 6
2021-02-25 14:03 ET
STAAR Surgical Co published news for 2020 q4
SEC form 10
2021-02-24 16:15 ET
STAAR Surgical Co published news for 2020 q4
SEC form 6
2021-02-24 16:10 ET
STAAR Surgical Co published news for 2020 q4
SEC form 6
2021-01-26 12:42 ET
STAAR Surgical Co published news for 2020 q4
SEC form 6
2021-01-11 06:03 ET
STAAR Surgical Co published news for 2020 q4
SEC form 6
2020-11-05 16:51 ET
STAAR Surgical Co published news for 2020 q3
SEC form 10
2020-11-04 16:10 ET
STAAR Surgical Co published news for 2020 q3
SEC form 6
2020-11-04 16:06 ET
STAAR Surgical Co published news for 2020 q3
SEC form 6
2020-10-07 20:03 ET
STAAR Surgical Co published news for 2020 q3